Wen-Ching Han

USPTO Granted Patents = 27 (Patent Applications = 2)

CIPO Patents = 1 (Patent Applications = 4)

EPO Patents = 12 (Patent Applications = 8)

Average Co-Inventor Count = 6.2

ph-index = 6

Forward Citations = 182(Granted Patents)

Location History:

Trenton, NJ (US) (1986)
Holland, PA (US) (1998)
Newton, PA (US) (2006)
Newtown, PA (US) (1996 - 2019)

Company Filing History:

25 out of 3,681

Bristol-myers Squibb Compnay

patents

2 out of 1,624

E. R. Squibb Sons, Inc.

patents

Years Active: 1986-2019

Loading Chart...

27 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10174024 - 5H-pyrido[3,2-B]indole compounds as anticancer agents (2019-01-08),

2. 9751879 - Tricyclic compounds as anticancer agents (2017-09-05),

3. 9725449 - Tricyclic compounds as anticancer agents (2017-08-08),

4. 9492460 - Carbazole compounds useful as bromodomain inhibitors (2016-11-15),

5. 9427442 - Fluoroalkyl and fluorocycloalkyl 1,4-benzodiazepinone compounds (2016-08-30),

6. 9273075 - Prodrugs of 1,4-benzodiazepinone compounds (2016-03-01),

7. 9242941 - Alkyl, fluoroalkyl-1,4-benzodiazepinone compounds (2016-01-26),

8. 9242940 - N-substituted bis(fluoroalkyl)-1,4-benzodiazepinone compounds (2016-01-26),

9. 9133139 - Fluoroalkyl-1,4-benzodiazepinone compounds (2015-09-15),

10. 8067582 - Fused heterocyclic compounds useful as modulators of nuclear hormone receptor function (2011-11-29),

11. 7846931 - Pyrrolotriazine compounds as kinase inhibitors (2010-12-07),

12. 7468439 - Alkylene bridged sultam compounds useful as modulators of nuclear hormone receptor function (2008-12-23),

13. 7417040 - Fused tricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3 (2008-08-26),

14. 7378426 - Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3 (2008-05-27),

15. 7297695 - Pyrrolotriazine compounds as kinase inhibitors (2007-11-20),

Title: **Wen-Ching Han: Innovator in Anticancer Compound Research**

Introduction

Wen-Ching Han is an accomplished inventor based in Newtown, PA, USA, with an impressive portfolio of 27 patents to his name. His work primarily focuses on the development of novel tricyclic compounds, which have shown promise as anticancer agents. Through his innovative research, he has significantly contributed to the field of pharmaceutical sciences.

Latest Patents

Among his latest patents, Wen-Ching Han has developed 5H-pyrido[3,2-B]indole compounds as anticancer agents. This invention revolves around tricyclic compounds that are designed to be used in pharmaceutically acceptable compositions for treating various disorders, particularly cancer. Additionally, he has patented other tricyclic compounds that serve similar purposes in treating various health conditions.

Career Highlights

Wen-Ching Han has built a reputable career in the pharmaceutical industry, having worked with leading organizations such as Bristol-Myers Squibb Company and E.R. Squibb & Sons, Inc. His innovative contributions have been instrumental in advancing drug development and therapeutic applications.

Collaborations

Throughout his career, Wen-Ching Han has collaborated with notable professionals in the field, including Ashvinikumar V Gavai and Derek J Norris. These partnerships have allowed for the exchange of ideas and fostered advancements in research and development for cancer treatments.

Conclusion

Wen-Ching Han's dedication to innovation in the realm of pharmaceutical compounds has made a significant impact. His ongoing work in developing anticancer agents reflects his commitment to finding effective therapies that could change the lives of many facing serious health challenges. With 27 patents and a history of collaboration with esteemed colleagues, he continues to be a vital force in the pursuit of medical advancements.

This text is generated by artificial intelligence and may not be accurate.